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Productive replication of human immunodeficiency virus type 1 (HIV-1) in brain macrophages and microglia
is a critical component of viral neuropathogenesis. However, how virus-macrophage interactions lead to
neurological disease remains incompletely understood. Possibly, a differential ability of virus to replicate in
brain tissue macrophages versus macrophages in other tissues underlies HIV-1 neurovirulence. To these ends,
we established systems for the isolation and propagation of pure populations of human microglia and then
analyzed the viral life cycles of divergent HIV-1 strains in these cells and in cultured monocytes by using
identical viral inocula and indicator systems. The HIV-1 isolates included those isolated from blood, lung
tissue, cerebrospinal fluids (CSF), and brain tissues of infected subjects: HIV-1ADA and HIV-189.6 (from
peripheral blood mononuclear cells), HIV-1DJV and HIV-1JR-FL (from brain tissue), HIV-1SF162 (from CSF),
and HIV-1BAL (from lung tissue). The synthesis of viral nucleic acids and viral mRNA, cytopathicity, and
release of progeny virions were assessed. A significant heterogeneity among macrophage-tropic isolates for
infection of monocytes and microglia was demonstrated. Importantly, a complete analysis of the viral life cycle
revealed no preferential differences in the abilities of the HIV-1 strains tested to replicate in microglia and/or
monocytes. Macrophage tropism likely dictates the abilities of HIV-1 to invade, replicate, and incite disease
within its microglial target cells.
The human immunodeficiency virus (HIV) invades the cen-
tral nervous system (CNS) early following viral infection but
produces brain disease only years later. During the periods of
progressive immunosuppression, from 15 to 25% of infected
individuals develop cognitive and motor abnormalities referred
to as the HIV type 1 (HIV-1)-associated dementia complex
(ADC) (21, 44, 45). Interestingly, and despite the significant
neurological impairments observed in ADC, cells of neural
origin (neurons, oligodendrocytes, and astrocytes) are rarely
infected in affected brain tissue (47). More than a decade of
research led to a consensus that the clinical and neuropatho-
logic abnormalities seen in ADC are likely a result of viral
infection of mononuclear phagocytes (microglia and blood-
derived brain macrophages) (27, 51, 56). Microglia, the resi-
dent macrophages of the brain, were first described nearly six
decades ago by del Rio Hortega (7, 8), but as yet their func-
tional significance in health and disease remains elusive. The
role of mononuclear phagocytes in HIV neuropathogenesis is
highlighted by HIV encephalitis (11, 55), in which multinucle-
ated giant cells (MGC) and perivascular macrophages are hall-
marks of brain pathology (2, 10, 46). Importantly, a recent
study demonstrated that the number of immunocompetent
brain macrophages is the best correlate for neurological dis-
ease in ADC (18).
It is well established that all HIV-1 neuroinvasive isolates
are macrophage tropic (15). However, the degree of viral rep-
lication in brain tissue may not always predict disease progres-
sion. Thus, it was hypothesized that a class of “neurotropic”
HIV-1 isolates that preferentially infect microglia and incite
disease exists (43, 50). Infected microglial cells secrete neuro-
toxins that serve to amplify the pathological and clinical man-
ifestations of ADC. Such a neuropathogenic mechanism is
unique among neurovirological disorders. Indeed, for herpes
simplex virus, cytomegalovirus, measles virus (subacute scle-
rosing panencephalitis), and other forms of viral encephalitis,
productive viral replication occurs in neurons and is associated
with direct neuronal cytopathicity (22). Neuronal loss is caused
as a direct consequence of viral infection. Alternatively, for
parainfectious encephalomyelitis (mumps, measles, and ru-
bella viruses), the virus produces neurological disease through
autoimmune mechanisms (23). For such diseases, virus cannot
be demonstrated in the CNS yet an intense inflammatory re-
action in the brain produces profound perivascular demyelina-
tion, presumably mediated by host immune responses elicited
as a consequence of peripheral viral replication.
Whether or not HIV is truly neurotropic remains unre-
solved. A recent study of the viral determinants for simian
immunodeficiency virus neurovirulence showed that although
the envelope glycoprotein determined macrophage tropism,
sequences from the transmembrane glycoprotein-encoding
portion of the same gene along with nef conferred neuroviru-
lence (35). Such genetic signatures have not as yet been dem-
onstrated conclusively for HIV (12, 28, 31, 43, 46, 49). None-
theless, if such subsets of HIV do exist and produce
neurological impairments, perhaps by preferentially infecting
microglia, such neurotropic viruses could have important im-
plications in viral neuropathogenesis. In support of this con-
cept, a recent report by Strizki and colleagues (50) demon-
strated that specific HIV-1 strains show preferential abilities to
replicate in microglia versus monocytes. However, the study
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examined only viral p24 production as a marker for HIV-1
replication. Quantitative assessments of the viral life cycle,
beginning with the formation of proviral DNA and leading to
the production of infectious progeny virions, had not been
determined.
To investigate whether specific HIV-1 strains have a prefer-
ential ability to replicate in microglia, we quantitatively evalu-
ated the viral life cycle in monocytes and microglia after virus
exposure. We performed quantitative comparisons of the syn-
thesis of viral nucleic acids in both cell types and determined
productive replication by measuring reverse transcriptase (RT)
activity in cell culture fluids. We show that a panel of viral
isolates recovered from peripheral blood mononuclear cells
(PBMCs), cerebrospinal fluid (CSF), and lung and brain tis-
sues of infected patients exhibit differential levels of replication
in monocytes that are identical to those observed in microglia.
MATERIALS AND METHODS
Reagents. Viral isolates HIV-1JR-FL (29), HIV-1BAL (14), HIV-189.6 (6), and
HIV-1SF162 (5) were obtained from the AIDS Research and Reference Reagent
Program, National Institute of Allergy and Infectious Diseases. HIV-1ADA was
isolated from PBMC of a patient with AIDS as previously described (17). HIV-
1DJV was obtained by monocyte cocultivation from brain tissue of a patient who
died of dementia (20). All viral strains were propagated on monocytes. HIV-1LAI
(41) and HIV-1YU-2 (34) proviral plasmid DNAs were generous gifts from
Michael Emerman and Beatrice Hahn, respectively. The isolates HIV-1LAI and
HIV-1YU-2 were rescued with a 293T packaging system (40). Briefly, episomal
forms of the HIV-1 clones were used to transfect human kidney epithelial cells,
the 293T cell line, in a transient-expression system. The resultant high-titer
cell-free virions were used to infect monocytes or microglia. HIV-1JR-FL, HIV-
1DJV, and HIVYU-2 were the neurotropic strains analyzed, as all were derived
from brain tissue of infected subjects with HIV encephalitis. Table 1 provides a
summary of the viral isolates used in this study. Antibodies to CD68 and
HAM-56 (macrophages), glial fibrillary acidic protein (GFAP; astrocytes), and
von Willebrand factor (endothelial cells) were purchased from Dako Corp.,
Carpinteria, Calif. The antibodies to neurofilament (NF), fluorescein isothiocya-
nate (FITC)-conjugated antibodies to mouse immunoglobulin G (IgG) F(ab9)2
fragments, and FITC- and rhodamine-conjugated antibodies to rabbit IgG
F(ab9)2 fragments were procured from Boehringer Mannheim Corp., Indianap-
olis, Ind.
Isolation of microglia. Fetal brain tissue (gestational age, 14 to 20 weeks) was
obtained from elective abortion procedures performed in full compliance with
National Institutes of Health and University of Nebraska Medical Center ethical
guidelines. The tissue was washed with cold Hanks balanced salt solution (Me-
diaTech, Herndon, Va.) supplemented with Ca21 and Mg21 and then was di-
gested with 0.25% trypsin (Sigma Chemical Co., St. Louis, Mo.) for 30 min at
37°C. Trypsin was neutralized with fetal bovine serum (FBS), and the tissue was
further dissociated to obtain single-cell suspensions. The cells were resuspended
in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) supplemented with a
mixture containing 10% heat-inactivated FBS, 1,000 U of purified recombinant
human macrophage colony stimulating factor (MCSF) per ml (a generous gift
from Genetics Institute, Cambridge, Mass.), penicillin and streptomycin (50
mg/ml), and 100 mg of neomycin per ml. The mixed culture was maintained under
10% CO2 for 7 days, and the medium was fully replaced to remove any cell
debris. The microglia cells released with further incubation were collected and
purified by preferential adhesion. Microglia were cultured as adherent monolay-
ers at a density of 5 3 104 cells/well in 96-well plates, and floating cells were
removed after 4 h. The adherent microglia preparations (.98% pure) were
identified by CD68 immunostaining. Replicate cultures were used for viral in-
fections.
Isolation and cultivation of monocytes. PBMCs were obtained from HIV-1-,
HIV-2-, and hepatitis B virus-seronegative donors by leukopheresis and were
purified by countercurrent centrifugation to generate pure populations of mono-
cytes (17). Cell suspensions were found to be .98% pure monocytes by Wright-
staining, nonspecific esterase, granular peroxidase, and CD68 immunostaining
assays. Cells were cultured in DMEM supplemented with 10% heat-inactivated
pooled human serum–10 mg of ciprofloxacin (Sigma) per ml–50 mg of gentamicin
(Sigma) per ml–1,000 U of MCSF per ml. All reagents were prescreened and
found to be negative for endotoxin (,10 pg/ml; Associates of Cape Cod, Woods
Hole, Mass.) and mycoplasma contamination (Gen-Probe II; Gen-Probe, San
Diego, Calif.).
HIV-1 infection of monocytes and microglia. Monocytes and microglia were
cultured on 96-well plates (Costar Corp., Cambridge, Mass.) at densities of 105
and 5 3 104 cells/well, respectively, for 7 days prior to infection with HIV-1. The
cell-free viral inoculum used for each experiment was standardized for all ex-
periments by RT activity (2 3 105 cpm/106 cells). Each experiment was per-
formed in triplicate determinations. The culture medium was exchanged twice
weekly, and samples were collected for RT activity measurement. RT activity was
determined by incubating 10 ml of sample with a reaction mixture consisting of
0.05% Nonidet P-40 (Sigma), 0.25 mg of oligo(dT) per ml, 10 mg of poly(A)
(Pharmacia Fine Chemicals, Piscataway, N.J.) per ml, 150 mmol of KCl per liter,
15 mmol of MgCl2 per liter, 5 mmol of dithiothreitol (Sigma) per liter, and
[3H]dTTP (2 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) in Tris-HCl
buffer (pH 7.9) for 24 h at 37°C. Radiolabeled nucleotides were precipitated on
paper filters in an automatic cell harvester (Skatron, Sterling, Va.) with cold 10%
trichloroacetate and 95% ethanol. The incorporated radioactivity was measured
by liquid scintillation spectroscopy (26). Adherent monolayers of monocytes and
microglia were incubated with HIV-1 for 4 h at 37°C. The inoculum was with-
drawn, and residual virus was washed off with fresh culture medium. Samples of
culture supernatant were collected by medium exchange twice weekly for RT
analysis. Viability of infected cells was measured by conversion of 3-(4,5-di-
methylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) to purple formazan.
PCR analysis of synthesis of viral nucleic acids. Monocytes (3 3 106 cells/well)
and microglia (5 3 105/well) were cultured on six-well plates (Costar Corp.) and
infected with HIV-1 as described above. Prior to infection, the HIV-1 cell-free
stocks were treated with DNase I for 30 min at 37°C (57). At 8, 24, 48, 72, and
96 h postinfection, samples were collected for RT analysis and the residual
medium was washed off with fresh phosphate-buffered saline (PBS; Sigma). The
cells were then scraped in 1 ml of PBS. The resultant cell pellet was used for the
extraction of cellular DNA with the Iso-quick nucleic extraction kit (ORCA
Research Inc., Bothell, Wash.). The DNA was resuspended at a concentration of
104 cell equivalents/ml. PCR was performed to identify early (primers to long
terminal repeat [LTR] U3/R), intermediate (primers to pol I and J regions), and
late (primers to LTR U3/gag) products of reverse transcription (57). PCR prim-
ers to gag and nef regions of the viral genome were used to detect the episomal
forms containing one and two LTRs (one- and two-LTR circles, respectively) (3,
4, 57). Standard HIV-1 cDNAs were prepared by simultaneous amplification on
serial twofold dilutions of DNA extracted from 8e5 cells that harbor defective
HIV-1 proviruses (13). Extrachromosomal one-LTR standards were generated
by PCR on HIV-1LAI-infected primary peripheral blood lymphocytes. Amplified
products were hybridized to radiolabeled oligonucleotide probes and quantified
on a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.).
Immunocytochemistry. Microglia were seeded on 8-mm-diameter chamber
slides (Nunc Inc., Naperville, Ill.) and were cultured as described above. Cells
were fixed in an ice-cold absolute acetone-methanol (1:1) mixture for 15 min at
220°C and then incubated with monoclonal antibodies (MAb) to CD68 or
HAM-56 (at a dilution of 1:50) or to GFAP at a 1:100 dilution. Additional MAbs
to HLA-DR, NF, CD14, and vimentin were from Boehringer Mannheim Corp.
and were used at a 1:50 dilution. Antibodies to HIV-1 p24, galactocerebrocide
(Gal-C; for oligodendrocytes), and von Willebrand factor were from Dako and
were used at 1:5, 1:50, and 1:200 dilutions, respectively. Immunostaining was
visualized by incubating the preparations with antibodies to mouse IgG F(ab9)2
fragments conjugated to FITC (at a 1:100 dilution) for p24, CD68, HLA-DR,
CD14, and vimentin or antibodies to mouse IgM F(ab9)2 fragments conjugated
to tetramethyl rhodamine isothiocyanate (TRITC; Boehringer) (at a 1:100 dilu-
tion) for HAM-56. Anti-rabbit IgG F(ab9)2 fragments conjugated to FITC (for
GFAP) and rhodamine (for Gal-C and von Willebrand factor) were used at a
1:100 dilution. Antigen-reactive cells were viewed on a Nikon Microphot-FXA
microscope (Nikon, Tokyo, Japan).
Electron microscopy. Microglia were placed on 12-mm-diameter coverslips
(105 cells/coverslip) and cultured as described above. After viral infection, cells
were fixed at days 7 and 21 postinfection with 2.5% glutaraldehyde, washed with
cacodylate buffer, postfixed in 1% osmium tetroxide, and then dehydrated and
embedded in LX 112 (Ladd Research Industries, Burlington, Vt.). Ultrathin
sections were stained with uranyl acetate and lead citrate and then examined on
TABLE 1. Panel of HIV-1 isolates used to compare monocyte and
microglial susceptibilities to HIV-1 infection
HIV-1 strain Source Tropism Reference
HIV-1JR-FL Brain tissue of patient with
HIV-1 dementia
MOa 29
HIV-1DJV Brain tissue of patient with
HIV-1 dementia
MO 20
HIV-1BAL Infant lung tissue MO 14
HIV-1SF162 CSF
b of a patient with AIDS MO 5
HIV-1ADA PBMC of patient with AIDS MO 17
HIV-189.6 PBMC of patient with AIDS MO 6
HIV-1YU-2 Brain tissue of patient with
AIDS
MO 34
HIV-1LAI PBMC of patient with AIDS T-cell 41
a MO, macrophage.
b CSF, cerebrospinal fluid.
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a Philips EM 410 electron microscope (Eindhoven, The Netherlands) as previ-
ously described (37).
RESULTS
Characterization of primary human fetal microglia. De-
tailed morphological and immunocytochemical characteriza-
tions of purified microglia cells were performed. The microglia
were collected as a nonadherent layer from the mixed brain
cell cultures and seeded on chamber slides as adherent cells.
The microglia differentiated with time from an ameboid form
and then developed processes that extended to several times
the size of their initial small oval cell bodies (Fig. 1A and D,
respectively). Cultured microglia were stained with antibodies
to cell-specific markers for macrophages (CD68 and HAM-56)
(Fig. 1A and B), for astrocytes (GFAP) (Fig. 1H), for endo-
thelial cells (von Willebrand factor), for oligodendrocytes
(Gal-C), and for neurons (NF) (data not shown) to establish
purity. The cells were .98% pure on the basis of these char-
acteristics. Double immunostaining with HAM-56 and GFAP
showed that only HAM-56-positive cells were present in the
culture and that none of the cells reacted with GFAP (Fig. 1G
and H). Double immunostaining with HLA-DR, a marker for
cell activation, and HAM-56 showed that the percentage of
HLA-DR- and HAM-56-double-positive cells was low (,25%)
and that the cells expressed HLA-DR weakly (Fig. 1E and F).
This result was distinct from that previously reported by Lee et
al. (33), demonstrating that cultured fetal microglia were
highly positive for HLA-DR. Staining for vimentin, a marker
for cytoskeletal proteins, clearly showed the cell bodies and
unique processes of microglial cells (Fig. 1D). Interestingly,
about 50% of the microglial cells were immunoreactive for
CD14, the receptor for bacterial lipopolysaccharide (36), and a
marker believed to distinguish adult monocytes from microglia
(52, 53).
Comparative analysis of HIV-1ADA infection of monocytes
and microglia. With the establishment of highly purified hu-
man microglia, we compared levels of viral infection by using a
prototypic macrophage-tropic viral strain, HIV-1ADA. The ac-
cumulations of viral nucleic acids by PCR in monocytes and
microglia infected with equivalent viral inocula were deter-
mined. The results are shown in Fig. 2. The use of zidovudine
(AZT) served as an internal control. In cells treated with AZT,
intermediate and late products of reverse transcription were
not detected. The viral DNA products identified in the HIV-
1ADA-inoculated cultures represent only de novo HIV-1 DNA
synthesis. In both monocytes and microglia both intermediate
and late products were detected at 8 h postinfection (Fig. 2).
The episomal forms of the viral nucleic acids (one-LTR circles)
were also observed in monocytes and microglia at 8 h postin-
fection. As the episomal forms of the viral DNA indicate the
completion of viral nucleic acid synthesis and the successful
nuclear import across the nuclear membrane, our data show
that under the culture conditions used, both monocytes and
microglia support a complete cycle of synthesis of viral DNA,
as early as 8 h after viral exposure. The experiment was re-
peated for three individual donors for monocytes and micro-
glia, and similar results were obtained. The ratios of early, inter-
mediate, and late products of viral cDNA synthesis to a
mitochondrial gene (the internal control for extraction of ex-
trachromosomal DNA) were also determined, and similar ki-
netics were observed for all products of HIV-1 proviral DNA
synthesis (data not shown). The peak accumulations of late
products were at 48 h postinfection for monocytes (Fig. 2) and
microglia. Late-product accumulation reached a peak at 48 h
and did not increase significantly thereafter.
We next examined the replication profiles of HIV-1ADA in
monocytes and microglia over a period of 3 to 4 weeks (Fig. 3A
and B, respectively). As virus-induced cytopathicity could af-
fect the levels of virus produced, we also examined the viability
of cells at specific times during the course of infection (Fig. 3C
and D). Both monocytes and microglia supported productive
replication of HIV-1ADA weeks after virus exposure. At days
14 and 21 postinfection, there was significant cell death ob-
served for both cell types, and the RT production subsequently
decreased. This experiment was repeated with three separate
donors of microglia and was performed with three or more
replicates. Thus, the synthesis of HIV-1 proviral DNA in
monocytes and microglia infected with HIV-1ADA occurs at
equivalent rates and both cell types support productive viral
replication.
Morphological, ultrastructural, and immunocytochemical
studies of HIV-1ADA-infected monocytes and microglia. Mor-
phological and immunocytochemical characterizations of HIV-
1ADA-infected monocytes and microglia were performed.
HIV-1 infection of microglia caused the fusion of individual
cells and the formation of multinucleated syncytia, similar to
infection of monocytes (Fig. 4) (5). The cytopathic effects were
virtually indistinguishable in monocytes and microglia despite
the fact that uninfected microglia bear longer processes and
are bipolar compared to ameboid monocytes with relatively
short processes.
By transmission electron microscopy (TEM), microglia cells
showed typical ultrastructural features of fully differentiated
macrophages, with well-developed cisternae of the endoplas-
mic reticulum, prominent Golgi apparatus, numerous elon-
gated mitochondria, lysosomes, lipid droplets, vacuoles, and
intermediate cytoplasmic filaments (Fig. 4C). Most of the mi-
croglial phagosomes contained dense products of myelin deg-
radation. The cells had long cytoplasmic processes and tightly
contacted one another, forming gap junctions. The cytoplasmic
membranes of the microglia were uneven with conspicuous
filopodia. Typical cytopathic effects (in MGC) following viral
infection were seen by TEM (Fig. 4D). Such cells with several
nuclei showed the same ultrastructural characteristics as unin-
fected cells, including numerous phagosomes with myelin rem-
nants. In addition, typical mature and immature lentiviral par-
ticles in association with cytoplasmic vacuoles or cell
membranes (Fig. 4E and F) were detected.
Immunocytochemical evaluation of monolayer cultures of
microglia infected with HIV-1ADA showed that .50% of cells
were consistently HIV-1 p24 positive 7 days after infection
FIG. 1. Immunocytochemical characterization of microglia cells. Microglia cells were collected from mixed cultures of glia and purified by preferential adhesion.
The cells were cultured on Chamber-Tech slides as adherent monolayers for 7 days. They were then fixed with cold acetone-methanol (1:1) for 15 min and treated with
anti-CD68 (A) or anti-HAM-56 (B) to confirm their identity. The cells were immunoreactive for CD14 (C). Incubation with vimentin (D) demonstrated processes
extending from the cell bodies. Double immunostaining for HLA-DR and HAM-56 revealed the presence of major histocompatibility complex class II on some cells.
The preparations were devoid of any astrocytes as demonstrated by double labeling with HAM-56 (G) and GFAP (H), an astrocyte marker. Positive staining was
visualized by anti-mouse IgG labeled with FITC for CD68, vimentin, CD14, and HLA-DR. Anti-mouse IgM labeled with TRITC was used for HAM-56. GFAP staining
was visualized with anti-rabbit rhodamine. All observations were made on a Nikon Microphot FXA microscope with appropriate filters. Original magnifications, 3200
(A, B, C, D, E, and F) and 3400 (G and H).
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(Fig. 4I). MGC double immunoreactive for CD68 and
HAM-56 were seen (Fig. 4G and H). Cells obtained from
multiple donors (eight in all) of varying gestational ages (15 to
20 weeks) were cultured and infected on a routine basis and
yielded similar results in terms of purity, morphology, and
susceptibility to infection with HIV-1ADA.
Analysis of viral DNA synthesis in monocytes and microglia
infected with a panel of HIV-1 isolates. An analysis of HIV-
1ADA-infected monocytes and microglia showed that there
were no easily detectable differences in the two cell types with
regard to the cell’s ability to support productive viral replica-
tion. To expand upon these observations, we investigated the
FIG. 2. Identification of HIV-1 DNA in infected monocytes and microglia. Cells were infected, as described in Materials and Methods, with HIV-1ADA. At specified
times postinfection, supernatant samples were collected for RT determination and the cells were fractured for viral DNA analysis. Primers that specifically amplified
early, intermediate, and late products of RT were used. The PCR-amplified products were quantified on a PhosphorImager after hybridization. A representative
experiment is shown.
FIG. 3. Replication profiles of HIV-1ADA-infected monocytes and microglia. Adherent layers of monocytes (105 cells/well) and primary human fetal microglia (5 3
104 cells/well) were cultured with MCSF for 7 days and then infected with HIV-1ADA. Virus was removed after a 4-h incubation. Culture fluids were collected every
2 days for RT analysis for both monocytes (A) and microglia (B). All experiments were performed with three separate donor cells and analyzed in triplicate
determinations. Cell viability was measured in triplicate by determining MTT activity at weekly intervals for the infected monocytes (C) and microglia (D). Error bars
represent standard deviations.
3344 GHORPADE ET AL. J. VIROL.
 
synthesis of viral DNA in monocytes (Fig. 5) and microglia
(Fig. 6) infected with a panel of macrophage-tropic and
lymphotropic viruses that included HIV-1BAL, HIV-1DJV,
HIV-1SF162, HIV-1JR-FL, HIV-189.6, and HIV-1LAI.
The synthesis of early, intermediate, and late products of
reverse transcription and the presence of episomal forms of the
viral nucleic acids were determined to assess successful nuclear
import of the preintegration complex of HIV-1 proviral DNA.
As shown with HIV-1ADA, in cells treated with AZT, interme-
diate and late products were not detected. This was consistent
for all isolates. Thus, the products identified in the monocyte
cultures inoculated with HIV-1 represent de novo synthesis. In
monocytes, both intermediate and late products were detected
as early as 8 h postinfection for HIV-1BAL, HIV-1DJV, HIV-
1SF162, HIV-1JR-FL, and HIV-189.6 (Fig. 5A, B, and C). HIV-1
late products were not observed in HIV-1LAI-infected mono-
cytes (Fig. 5C). The episomal forms of the viral nucleic acids
containing one LTR were detected in monocytes at 24 h
postinfection for all macrophage-tropic strains (Fig. 5). HIV-
1YU-2 showed results similar to those illustrated for HIV-1BAL
and HIV-1DJV (data not shown). Analysis of viral mRNA was
performed in infected monocytes by techniques described previ-
FIG. 4. Morphological, ultrastructural, and immunocytochemical characterization of HIV-1ADA-infected microglia. Adherent monolayers of microglia were
infected with HIV-1ADA or were left as uninfected controls. At 14 days after viral inoculation, cells were fixed with a mixture of acetone and methanol (1:1) for 15 min
and then stained by a modified Wright’s stain method. Uninfected (A) and HIV-1-infected (B) microglia are shown. Original magnification (A and B), 3200.
Ultrastructural features of virus-infected and uninfected human microglia are shown in panels C to F. Cytoplasm of uninfected microglia cells (C) contains cisternae
of the endoplasmic reticulum, prominent Golgi apparatus, mitochondria, vacuoles, and phagosomes. Long cytoplasmic processes contact one another forming gap
junctions. HIV-1-infected multinucleated microglia cells (D) show the same ultrastructural characteristics as uninfected ones, including multiple phagosomes with dense
products of myelin degradation. In addition, typical mature (F; arrow) and immature (E; arrow) lentiviral particles are detected within cytoplasmic vacuoles of
HIV-1-infected microglia cells. Panels E and F present higher magnifications of the cell shown on panel D. Original magnifications, 32,000 (C), 345,000 (D), 346,000
(E), and 340,000 (F). The results of immunocytochemical studies of HIV-1ADA-infected microglia are shown in panels G to I. HIV-1ADA-infected microglia were
stained for monocyte lineage markers CD68 (G) and HAM-56 (H). MGC immunoreactive for both CD68 and HAM-56 are illustrated. HIV-1 p24 immunoreactivity
is shown for the MGC and also for single cells on day 7 following viral infection (I). Original magnification (G to I), 3200.
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ously for in situ hybridization (16, 39), and similar trends were
observed (data not shown).
Next, the accumulations of viral nucleic acids in microglia
infected with HIV-1BAL, HIV-1DJV, HIV-189.6 (Fig. 6A), HIV-
1JR-FL, and HIV-1SF162 (Fig. 6B) were determined. There was
considerable accumulation of the late products of HIV-1 pro-
viral DNA (identified by using LTR U3/gag regions) in micro-
glia for all isolates. The trend was similar to that observed in
virus-infected monocytes. The accumulation of episomal forms
of the viral nucleic acids containing one LTR was detected at
72 h in microglia for both HIV-1JR-FL and HIV-1SF162. As the
episomal forms of viral DNA indicate completion of viral nu-
cleic acid synthesis and successful nuclear import, the data
show that with comparable levels of virus inocula both micro-
glia and macrophages support a complete cycle of viral DNA
synthesis. The extrachromosomal forms of viral cDNA con-
taining two LTRs, which are low-abundance circle forms of the
viral DNA (two-LTR circle), were also detected in microglia
for both HIV-1JR-FL and HIV-1SF162 as early as 24 h postin-
fection (Fig. 6). In monocytes the two-LTR circle forms were
detected at 48 h postinfection (Fig. 5). For quantitative com-
parisons the ratios of the late products of reverse transcription
to that of a mitochondrial gene were also calculated, and these
ratios also reflected significant differences between viral strains
(a range of 0.01 [for HIV-1SF162] to 0.04 [for HIV-1ADA]). In
addition, the kinetics of HIV-1 RT products was evident for all
isolates used, as reflected by an increase in the early, interme-
diate, and late products with prolonged postinfection time
points. These were observed for all viral isolates (data not
shown). Moreover, the differences in the levels of productive
infection between the isolates were also evident. HIV-1DJV,
HIV-1BAL, HIV-1JR-FL, and HIV-1SF162 rapidly complete their
viral life cycles in both monocytes and microglia. The rates of
synthesis of proviral DNA in microglia infected with HIV-
1BAL, HIV-1DJV, HIV-1JR-FL, HIV-1SF162, and HIV-189.6 are
comparable to those observed in monocytes.
Analysis of progeny virion production in monocytes and
microglia infected with a panel of HIV-1 isolates. The produc-
tion of progeny virions was measured by determining RT ac-
tivity in culture fluids following HIV-1 infection in monocytes
and microglia. Figure 7 shows the kinetics of productive rep-
lication of the panel of HIV-1 isolates. All macrophage-tropic
strains productively infected both microglia and monocytes,
albeit at different levels. HIV-1LAI did not give rise to any
productive infection. Lee and colleagues (32) showed that
HIV-1IIIB, when used at a high multiplicity of infection, led to
infection of microglia. However, we did not find this for HIV-
1LAI, consistent with previous reports concerning T-tropic iso-
lates (54). More importantly, the pattern of the level of viral
replication was identical for monocytes and microglia. HIV-
1ADA, HIV-1DJV, and HIV-1BAL elicited very high levels of
productive infection in monocytes (Fig. 7A and B) and micro-
glia (Fig. 7C and D). HIV-1SF162 and HIV-189.6 gave incre-
mentally reduced RT activity levels. HIV-1YU-2, a molecular
clone directly obtained from infected brain tissue, also elicited
very high levels of progeny virus production in both microglia
and monocytes (data not shown). HIV-1YU-2 was rescued in a
high-efficiency packaging cell system (34, 40) and was used
directly for infection. The levels of virus produced were higher
for monocytes than for microglia, including HIV-1YU-2. HIV-
1SF162 and HIV-189.6 both reached peak RT activity later in
microglia (day 40 and day 32, respectively). A similar result was
seen in monocytes, as peak RT values were obtained on days
25 and 27, respectively. However, in general, peak RT values
were delayed in microglia compared to monocytes. One-way
analysis of group variance for both microglia and monocytes
showed that the differences within the strain groups were sig-
FIG. 5. Comparative analysis of the synthesis of viral nucleic acids in mono-
cytes infected with a panel of isolates. Monocytes were infected as described in
Materials and Methods with the panel of HIV-1 isolates: HIV-1BAL (BAL),
HIV-1DJV (DJV), HIV-1JR-FL (JRFL), HIV-1SF162 (SF162), HIV-189.6 (89.6),
and HIV-1LAI (LAI). At 8, 24, 48, and 96 h postinfection, supernatant samples
were collected for analysis of RT and the cells were collected for isolation of
DNA in PBS. The respective primers were used for amplifying early (LTR
U3/R), intermediate (pol I and J), and late (LTR U3/gag) products of reverse
transcription. The episomal forms of the viral DNA were amplified with primers
to the gag and nef regions. The PCR-amplified products were quantified on a
PhosphorImager after hybridization. A representative experiment is shown.
HIV-1BAL- and HIV-1DJV- (A), HIV-1SF162- and HIV-1JR-FL- (B), and HIV-
189.6- and HIV-1LAI-infected monocytes (C) were analyzed.
3346 GHORPADE ET AL. J. VIROL.
 
 
nificant (P , 0.0001). There was clear consistency for viral
strains in both microglia and monocytes. The viabilities of the
infected cells at specific time intervals after viral exposure were
also similar for monocytes and microglia (Fig. 8). HIV-1DJV
was highly cytopathic and led to significant cell death after 14
days of infection in both monocytes (Fig. 8A) and microglia
(Fig. 8B). HIV-189.6 was the least cytopathic in both cell types.
Interestingly, there was also consistency in the cytopathic ef-
fects observed in monocytes and microglia. These data dem-
onstrate a heterogeneity among macrophage-tropic HIV-1
strains for infection of monocytes and microglia. HIV-1ADA,
HIV-1DJV, and HIV-1BAL were highly productive in both cell
types while HIV-189.6 was significantly less so. HIV-1LAI did
not lead to productive viral replication in either monocytes or
microglia. For each of the strains tested both cell types were
equally susceptible to viral replication.
DISCUSSION
In this study we investigated whether the susceptibility to
HIV-1 infection differed between primary human microglia
and monocytes. Such differences, if found, could reflect a neu-
rotropic potential for HIV-1. We first established highly puri-
fied and well-characterized microglia systems and studied
HIV-1 replication at three different stages of the viral life cycle.
These included the synthesis of viral DNA and viral mRNA
(data not shown) and progeny virion production as indicated
by RT activity in culture supernatants. From all the data taken
together, we found that there was no significant difference in
the susceptibilities of the two cell types to HIV-1 infection.
Thus the ability of a given isolate to infect microglia or mono-
cytes may not be generally utilized as a signature to distinguish
between neurovirulent and macrophage-tropic viral strains.
Prior studies suggested that qualitative, not quantitative, prop-
erties of HIV-1 mainly determine clinical differences between
demented and nondemented patients (24). A report by Strizki
et al. (50) suggested that there is preferential HIV-1 infection
of microglia for select viral strains. However, if such a finding
were to be made for a small percentage of viral variants, it is
unlikely to be a generalized observation to explain neuroviru-
lent HIV-1 phenotypes. The ability of HIV-1 to produce dis-
ease within the CNS likely reflects multiple properties of virus-
host interactions that include but are not limited to host
genetic properties, the degree of immunosuppression, immu-
nologic factors (inside and outside the brain), the integrity of
the blood-brain barrier, the presence of opportunistic infec-
tions, and the virulence of the viral strain(s) that affects the
CNS, including the host cell range of the virus. The Strizki
findings may have added relevance to HIV neuropathogenesis
in the developed CNS, because the microglia obtained in their
work were from mature brain specimens.
Given their functional and morphological plasticity (25), mi-
croglia may play a unique role in HIV neuropathogenesis. The
question as to whether microglia differ functionally from
monocytes is unresolved. This question arises from the com-
mon origin of the two cell types. Despite their residence in the
brain, microglia cells originate outside the CNS and migrate
into the CNS in late embryonic life. It has also been previously
demonstrated that microglia tropism maps at a region of
HIV-1 env that similarly controls macrophage tropism (48).
Initial reports showed that fetal microglia obtained from first-
trimester tissue specimens were refractory to infection with
HIV-1 (42); however, it was later shown that cultured micro-
glia from second-trimester tissue and also adult microglia can
be infected with macrophage-tropic but not lymphocyte cell-
tropic isolates (54). Subsequently, two groups have shown that
at high infectivity doses, microglia cells can be susceptible to
infection with lymphocyte cell-tropic isolates but are subject to
donor variation (32, 50). We did not find any infection of
microglia with lymphocyte-tropic isolate HIV-1LAI at a viral
inoculate level equivalent to those for other isolates. Impor-
tantly, donor-to-donor variations were also not demonstrated.
The data support the notion that macrophage and microglial
tropisms for HIV-1 are similar.
HIV-1 is selectively localized within perivascular and infil-
trated parenchymal blood-derived macrophages and microglia
(9, 30, 51), suggesting a hematogenous entry of the virus to the
brain. Our data also suggest that it is the macrophage, rather
than the viral isolate, that regulates penetration by HIV-1 into
the CNS. The sequestration of virus in mononuclear phago-
cytes is a reservoir for HIV-1. The evolution of quasispecies of
virus could occur separately within the CNS. The fact that
there exists genetic variation in different HIV-1 isolates ob-
tained from different patients and from the same individual is
consistent with this hypothesis (19). However, when HIV-1
isolates originally obtained from brain tissue or blood were
FIG. 6. Comparative analysis of the synthesis of viral DNA in microglia
infected with a panel of HIV-1 isolates. Adherent layers of microglia were
infected with the panel of HIV-1 isolates, and at 24 and 72 h postinfection,
supernatant fluids were collected for analysis of RT activity and the cells were
collected for extraction of cellular DNA for PCR analysis. Early, intermediate,
and late products of RT were amplified as described in Materials and Methods.
Episomal forms of HIV-1 DNAs were detected with primers to gag and nef and
LTR R/U5 regions. The amplified products were analyzed by electrophoresis on
agarose gels and then hybridized to radiolabeled oligonucleotides to detect
specific regions of HIV-1 proviral DNA. The accumulated viral DNA products
were then quantified on a PhosphorImager. HIV-1DJV (DJV)-, HIV-1BAL
(BAL)-, and HIV-189.6 (89.6)-infected microglia (A) and HIV-1JR-FL (JR-FL)- and
HIV-1SF162 (SF-162)-infected microglia and infected microglia (B) are shown.
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compared, no significant difference in the comparative infec-
tivity in microglia and monocytes was found.
An important issue for this work is that we utilized primary
fetal microglia as target cells for HIV-1 infection. It is possible
that fetal cells behave differently from cultured adult microglia.
Indeed, the developing CNS is more susceptible to HIV-1
infection than the adult CNS (21). Future studies in which
adult and fetal microglia are compared (side by side) for viral
FIG. 7. Replication profiles of the panel of HIV-1 isolates in blood monocytes and microglia. Adherent monolayers of macrophages (105 cells/well) or microglia
(5 3 104 cells/well in a 96-well plate) were infected with comparable viral inocula. The infection proceeded for 4 h, after which the virus was removed. Culture
supernatant samples were withdrawn at specific time intervals over a period of 3 to 4 weeks. RT activity was assayed for both virus-inoculated and control uninfected
cells (A and C). Monocytes (A and B) and microglia cells (C and D) were infected with a panel of HIV-1 strains including HIVADA (ADA), HIV-1DJV (DJV), and
HIV-1SF162 (SF162) (A and C), HIV-1BAL (BAL), HIV-1JR-FL (JR-FL), and HIV-189.6 (89.6) (B and D), and HIV-1LAI (LAI) (D). Each isolate was examined in
triplicate. Representative results obtained with a single donor each are shown for monocytes and microglia. Error bars represent standard deviations.
FIG. 8. Viability profiles of HIV-1-infected monocytes and microglia. Monocytes (A) and microglia (B) infected with the panel of HIV-1 isolates were maintained
for 4 weeks. At days 7, 14, and 21 postinfection, the supernatant was withdrawn and the cells were incubated with 2 mg of MTT supplemented with 10% FBS for 45
min at 37°C. At the end of the incubation period, the MTT reagent was washed off and the formazan crystals were dissolved in 100 ml of dimethyl sulfoxide. The
absorbance was recorded at 490 nm. Each assay was performed in triplicate. Error bars represent standard deviations.
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infection may prove helpful in elucidating the unique abilities
that fetal brain tissue has for HIV-1 infection and for eliciting
neurological disease.
The presence of molecular variants of the virus is a reflection
of the fact that retroviral RT does not have any proofreading
function. For HIV-1 there is a potential change of nucleotides
at a rate of one for every 10,000 bp. That would bring about
one base substitution per genome in every replication cycle
(38). Studies comparing sequences of HIV-1 isolates from the
brain and blood show that the envelope region of HIV-1 se-
questers such mutations, indicating selection pressures. There
are some conserved elements identified in the V3 loop of
isolates derived from brains of demented patients compared to
the consensus sequence shown by Korber et al., LaRosa et al.,
Power et al., and Shimizu et al. (28, 31, 43, 49). This suggests
a potential overlapping pathway for selection of neurovirulent
isolates in different individuals. The importance of the V3 loop
sequences in determining tropism is controversial (46), as re-
cently it was demonstrated that the residues originally thought
to be critical for neurovirulence were also found in the majority
of nondemented patient samples. Also, all of the brain-derived
isolates lacked the proline residue at position 305, described
initially by di Stefano et al. and Power et al. (12, 43).
Thus, the issue of HIV-1 neurovirulence has been contro-
versial. Needless to say, there is evidence to suggest that it is
the qualitative property of the virus that determines disease
progression in patients. However, there have not been any
consistent data regarding a particular molecular property of
the virus to assign a signature for neurovirulence. We suggest
that it is the onset of the immune functions elicited by infection
of microglia by certain isolates, as distinct from those elicited
by infection of monocytes, that may be the basis for clinical
differences of disease progression. It is generally accepted that
the myriad of pathological manifestations of HIV-1 infection
result from the interplay of molecules mediating intercellular
interactions between infected microglia and macrophages, as-
trocytes, oligodendrocytes, and neurons, more specifically
through the elaboration of various cytokines and potential
neurotoxins (1, 15, 45). Clearly, the network of microglia in the
brain and their close proximity to the other neural elements
make them central candidates for the differential immune-
mediated manifestations of HIV-1-induced neurological dis-
ease.
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